TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04758728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Great saphenous vein stripping and varicectomies
Description: Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Great saphenous vein stripping and varicectomies
Description: Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Great saphenous vein stripping and varicectomies
Description: Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Topical
Description: Use of epinephrine/adrenaline solution 1:1000 topically

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: Use of normal saline solution NaCl 0,9% topically
Study: NCT00844090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylphenidate or placebo
Description: treat apathy to improve diabetes self care behaviors thereby improving glycemic control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate or placebo
Description: treat apathy to improve diabetes self care behaviors thereby improving glycemic control
Study: NCT04486508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermediate dose Enoxaparin/ unfractionated heparin
Description: Intermediate dose anticoagulation according to creatinine clearance and weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard prophylactic dose Enoxaparin/ unfractionated heparin
Description: Standard prophylaxis anticoagulation according to creatinine clearance and weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Statin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo to atorvastatin 20 mg
Study: NCT04249947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-PSMA-101 CAR-T cells
Description: P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-PSMA-101 CAR-T cells
Description: P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-PSMA-101 CAR-T cells
Description: P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-PSMA-101 CAR-T cells
Description: P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated
Study: NCT05385146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qigong
Description: Chan-Chuang qigong with breathing meditation for 15 weeks
Study: NCT02481076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowtron Hydroven and Coban2 Lite
Description: The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm

Intervention type: OTHER
Group type: OTHER
Intervention: Braun frame
Description: The leg is elevated on a Braun frame

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression bandage
Description: application of flowtron hydroven boot and compression bandage
Study: NCT03747848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group
Description: Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
Study: NCT03507855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced noise
Description: All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal
Description: No change in the normal operating room environment.
Study: NCT01536210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-162
Description: YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
Study: NCT03796312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tub Bathing
Description: The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sponge Bathing
Description: Sponge bathing is routine care of the clinic
Study: NCT02365935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A adjuvant chemotherapy
Description: In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B adjuvant chemotherapy
Description: In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT02048722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Given PO
Study: NCT00514618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
Study: NCT03924323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 8-weeks of treatment followed by 1-week taper down period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral administration of inactive substance once daily
Study: NCT01064271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone Tablets 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone Tablets 1 mg
Study: NCT01545388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks
Study: NCT02567188

Intervention type: OTHER
Intervention: MIRCERA
Study: NCT02136537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral NMES legs
Description: Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical therapy
Description: Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical therapy
Description: Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
Study: NCT00432900

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [(11)C]PBR28
Description: PET Ligand

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [(11)C]PBR28
Description: PET Ligand
Study: NCT02247466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium and Sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium and Sugammadex
Study: NCT01825200

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok
Description: A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Afluria
Description: Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
Study: NCT02570386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh embryo transfer
Description: Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen embryo transfer
Description: Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
Study: NCT03685175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formal study using hyperpolarized 13C-pyruvate injection
Description: Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feasible study using hyperpolarized 13C-pyruvate injection
Description: Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
Study: NCT04192240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB Training with external feedback
Description: WB during sit-to-stand and stepping with external feedback, follow by overground walking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WB Training without external feedback
Description: WB during sit-to-stand and stepping without external feedback, follow by overground walking.
Study: NCT01161810

Intervention type: OTHER
Intervention: Routine post burn rehabilitation therapy
Description: No testing outside of routine clinical rehabilitation will be performed
Study: NCT02718911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Administered IV
Study: NCT01132183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study: NCT02728063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactibiane Tolerance
Description: probiotics
Study: NCT03781466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage indicated by short cervix ≤25mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage indicated by short cervix ≤25mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
Study: NCT02604030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb function
Description: Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
Study: NCT05854420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified anterior Lamellar Recession
Description: ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
Study: NCT03565757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART intervention
Description: All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
Study: NCT00889941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: laser-assisted in situ keratomileusis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: laser-assisted in situ keratomileusis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: laser-assisted in situ keratomileusis
Study: NCT04168528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68GaNOTA-Anti-MMR-VHH2
Description: Injection of the radiopharmaceutical and PET/CT imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68GaNOTA-Anti-MMR-VHH2
Description: Injection of the radiopharmaceutical and PET/CT imaging
Study: NCT03894709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-centered care model
Description: Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
Study: NCT03589807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
Study: NCT02368457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Tocopherol
Description: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
Study: NCT03890003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study: NCT01640405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: modified FOLFOX6 + bevacizumab
Description: * Bevacizumab 5 mg/kg iv, day 1, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~  * LV 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Bevacizumab
Description: * Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~* LV 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).
Study: NCT04252274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir and Cobicistat
Description: Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
Study: NCT04419129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford UKA
Description: knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard TKA
Description: knee arthroplasty
Study: NCT01293253

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stair walking
Description: Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair walking
Description: Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active